Prediction of unilateral prostate cancer by the combination of transrectal ultrasonography-guided prostate biopsy and multi-parametric magnetic resonance imaging: A real-life experience

Jung Jun Kim, Taejin Kim, Hakjong Lee, Seok-Soo Byun, Sang Eun Lee, Gheeyoung Choe, Sung Kyu Hong

1 Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea, 2 Department of Radiology, Seoul National University Bundang Hospital, Seongnam, Korea, 3 Department of Urology, Seoul National University College of Medicine, Seoul, Korea, 4 Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea

* skhong@snubh.org

Abstract

Hemi-ablation of prostate cancer (PCa) requires an accurate prediction of laterality. Recently, multi-parametric magnetic resonance imaging (mpMRI) has recently been increasingly used to enhance clinical staging and characterization of tumor foci. Thus, we tried to investigate the real-life accuracy of combinatory approach of using both transrectal ultrasonound (TRUS)-guided prostatic biopsy and mpMRI in predicting the laterality of PCa. We reviewed the records of 335 men who were suspected of having unilateral PCa on multi- (≥ 12)-core TRUS-guided biopsy and preoperative mpMRI and subsequently had undergone radical prostatectomy (RP) at our institution. Based on the analysis of pathologic outcomes from RP, the performance of the combinatory approach in predicting the pathological laterality of PCa was evaluated. Pathology was classified to be unfavorable when showing a Gleason pattern of 4/5 or pT3/N1 features. Significant cancer was defined as non-organ-confined disease, having a Gleason pattern of 4/5, or showing a cancer volume of ≥ 0.5 mL. Among the 335 unilateral lobes not suspected to harbor tumor from either the TRUS biopsy or mpMRI, the actual absence rate of malignancy was only 13.7% from a pathologic analysis of RP specimens. Even among the 335 unilateral lobes not suspected to harbor tumor from either the TRUS biopsy or mpMRI, the actual absence rate of malignancy was only 13.7% from a pathologic analysis of RP specimens. Even among the 115 D’Amico low-risk group, the absence rate of malignancy was only 26.1% in unilateral lobes not suspected to harbor tumor. Among the 335 lobes, unfavorable pathology and significant cancer were not observed in 36.1% and 30.7%, respectively. The absence rates of unfavorable pathology and significant cancer among the D’Amico low-risk group were 56.5% and 47.8%, respectively. Meanwhile, the absence rate of dominant Gleason pattern 4 or 5 was 74.9% among the 335 total subjects. Our real-life clinical experience showed that the combination of multi-core TRUS-guided biopsy and mpMRI did not provide reliable accuracy in the prediction of true unilaterality of PCa.
Introduction

A widespread implementation of prostate-specific antigen (PSA) screening has contributed to earlier detection of prostate cancer (PCa) at lower stages, lower grades, and smaller tumor volumes [1]. Moreover, with advancements in minimally invasive treatment modalities, a wide variety of organ-sparing focal therapies for PCa have been introduced with the goal of minimizing complications [2]. Although focal therapies, such as high-intensity focused ultrasound (HIFU) and cryoablation, have not yet been regarded as the standard treatment modalities that can replace radical prostatectomy (RP) or radiation therapy, they have been acknowledged as having great potential. During the past decade, several reports have shown promising data regarding these organ-sparing therapies for localized PCa [3–6].

Meanwhile, a proper selection of candidates for focal therapy remains a major challenge in actual clinical practice. The success of focal therapy heavily depends on an accurate localization of significant tumor foci within the prostate. For hemi-ablation of PCa, accurate prediction of laterality of PCa is crucial. Traditionally, transrectal ultrasound (TRUS)-guided prostatic biopsy has been widely used to assess the laterality of tumor foci; however, the method was less than satisfactory with respect to its accuracy. To overcome such a limitation, multi-parametric magnetic resonance imaging (mpMRI) has been increasingly used to enhance clinical staging and characterization of tumor foci [7]. Recently, MRI-targeted biopsy has been advocated in hopes of preventing unnecessary biopsy and/or decrease the number of cores obtained to minimize patient burden [8]. However, the actual degree of accuracy of mpMRI remains controversial [9]. Thus, we tried to investigate the real-life accuracy of clinical staging using TRUS-guided prostatic biopsy and mpMRI, which is currently widely used in clinical setting, in predicting the laterality of PCa.

Materials and methods

Ethics statement

This retrospective study was approved by the Institutional Review Board (IRB) of Seoul National University Bundang Hospital (Seongnam, Republic of Korea). The approval number is B1706/402-115. The requirement for informed consent was waived. Personal identifiers were all removed and the data were anonymously analyzed.

Patients

Between January 2010 and July 2015, a total of 730 patients were diagnosed with localized PCa (clinical T1/T2) via extended multi (≥12)-core TRUS-guided biopsy, underwent preoperative mpMRI with ADC mapping, and subsequently received radical prostatectomy (RP) at a single tertiary center. Of these 730 patients, 335 men-who were suspected of having unilateral localized prostate cancer from preoperative clinical staging on multi (≥12)-core TRUS-guided biopsy and mpMRI, separately, and eventually underwent RP without any prior treatment were finally included in the present study. The pathological analyses including histopathologic mapping by quadri-mount section were performed in all 335 patients following RP. Predictive performance of the combination of pretreatment clinical parameters (multi (≥12)-core TRUS-guided biopsy, and mpMRI) in predicting the pathological laterality of PCa was evaluated.

Imaging protocol

MRIs were performed using a 3.0-T MR system (Intera Achieva 3.0T, Philips Medical Systems, Best, The Netherlands) equipped with phased-array cardiac 6-channel coil. Thirty minutes
prior to imaging, all patients were injected with 20 mg butylscopolamine (Buscopan, Boehringer Ingelheim Pharma, Ingelheim, Germany) intramuscularly to suppress bowel peristalsis. Axial diffusion-weighted (DW) images were acquired using single-shot echo planar imaging. The scan parameters were as follows: TR, 2,500–3,000 ms; TE, 56–65 ms; slice thickness, 3 mm; interslice gap, 1 mm; field of view, 180 mm×180 mm; matrix, 92×90; and number of excitations, 10. Diffusion encoding gradients were applied as a bipolar pair at b-values 0 and 1,000 s/mm². ADC maps were automatically generated on a pixel-by-pixel basis. MRI examinations were conducted at least 2 weeks after prostate biopsy.

**Image analysis**

Two experienced uro-radiologists with more than 10 years of mpMRI experience, who were blinded to all clinical variables including pathological outcome, graded the level of suspicion for PCa from mpMRI using the Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) scale from 1 to 5 in following manner: grade 1, highly unlikely to be present; grade 2, unlikely to be present; grade 3, equivocal; grade 4, likely to be present; and grade 5, highly likely to be present) [10]. MpMRI was considered negative in a unilateral prostatic lobe when no suspicious lesion was seen or when PIRADS grade was \( \leq 2 \) in that lobe.

**Histopathology acquisition and analysis**

For pathological examination, the surgical specimens were routinely fixed in formalin and embedded in paraffin following the standard protocols at our hospital. The paraffin-embedded tissue samples were cut in 4–6-µm-thick sections on a rotary microtome and subsequently stained with hematoxylin and eosin. Each slice was marked according to tissue orientation, annotated by slice number, fixed, and then paraffin embedded. Subsequently, 5-micron mount sections were cut from the paraffin-embedded tissue, mounted on glass slides, and stained with hematoxylin and eosin. The interface of the peripheral zone and transition zone, as well as all cancer foci were outlined with a marker on the glass slides by a genitourinary pathologist. Each cancer focus was assigned a Gleason score, calculated as the most predominant Gleason pattern plus the second most predominant Gleason pattern. A third Gleason pattern representing a minor tertiary component was included as the third grade, if and when present. In addition, the estimated percent of Gleason patterns 3, 4, and 5 were documented.

Two urological pathologists reviewed the stained sections and reported the final pathological results. The pathological stages and Gleason grades were determined according to the seventh edition of the American Joint Committee on Cancer staging system and the International Society of Urological Pathology, respectively [11] [12]. The whole mount section pathology, including histopathological topographic mapping reports after RP, was used to obtain information about the pTNM stage and Gleason score as well as tumor size and location.

Pathology was classified to be unfavorable when showing a Gleason pattern 4/5, or pT3/N1 features, [13]. Significant cancer was defined as non-organ-confined disease, having Gleason pattern 4/5, or showing a cancer volume of \( \geq 0.5 \) mL [14].

**Statistical analysis**

We first assessed the clinical characteristics of the cohort and the pathological outcome of the unilateral lobe not suspected to harbor tumor. The pathological outcomes were compared between the clinically low-risk group and high-risk group. Sensitivity analysis was performed to evaluate the accuracy of the combination approach in predicting the pathological outcome of each prostate lobe. Chi-square test was used for the comparison of pathological outcome and predictive performance. All statistical analyses were performed using SPSS 22.0 for
Windows (IBM® SPSS® version 22.0, IBM, Armonk, New York, USA). The p values were considered statistically significant when <0.01.

Results

Of the 730 patients who underwent TRUS-guided biopsy, mpMRI, and subsequently RP for the treatment of localized prostate cancer (T1/T2) at our institution between January 2010 and July 2015, there were 355 (45.9%) potential candidates for hemi-ablation who were suspected of having tumor only in the unilateral prostatic lobe from preoperative clinical staging (TRUS-guided biopsy, and mpMRI), as shown in Fig 1. The clinicopathological characteristics of these 335 men are summarized in Table 1. The median age and PSA were 65.1 years (45–82) and 7.8 ng/dl (2.2–21), respectively. Regarding the pathological outcome, among the 335 men, 34.3% had D’Amico low risk disease. The rates of locally advanced disease and local lymph node metastasis were 8.9% and 1.3%, respectively.

Table 2 shows the pathological outcomes of unilateral prostate lobes not suspected to harbor tumor from TRUS-guided biopsy and preoperative mpMRI. Among the 335 unilateral lobes, the absence rate of malignancy was only 13.7%. In 3.0% of patients, the extraprostatic extension and/or seminal vesicle invasion were observed on the unilateral side with no preoperative tumor suspicion.

Table 3 shows a comparison of the pathological outcomes of unilateral prostate lobes not suspected to harbor tumor preoperatively between the D’Amico low-risk group and D’Amico moderate to high-risk group. As can be expected, the pathologic stage and grade as well as tumor volume were observed to be more favorable among the low-risk group compared with the intermediate- to high-risk group. However, even among the 115 D’Amico low-risk group, the absence rate of malignancy was only 26.1%. Also the rate of Gleason 6 PCa was 30.4%.

Table 4 summarizes the pathological characteristics of unilateral prostate lobes not suspected to harbor tumor preoperatively by TRUS-guided biopsy and mpMRI. Among the 335 total subjects, unfavorable pathology and significant cancer were not observed in 36.1% and 30.7%, respectively. The absence rates of unfavorable pathology and significant cancer, among the D’Amico low-risk group were 56.5% and 47.8%, respectively. Meanwhile, the absence rates of dominant Gleason pattern 4 or 5 were 74.9% and 85.2%, respectively, among the 335 total subjects and the low-risk group only.

Table 5 demonstrates the sensitivity analysis outcome of the approach that combined TRUS biopsy and mpMRI (positive biopsy core or PI-RAD≥3 lesion) in predicting the overall PCa, significant cancer, and unfavorable pathology in each prostate lobe.

Discussion

In this study, we observed that only about 14% of the potential candidates for hemi-ablation actually had true unilateral disease on final pathologic analysis of RP specimens. Moreover, although not many, some candidates even harbored locally advanced disease. Even when the analysis was limited to subjects in the low-risk group (PSA<10 ng/ml, Gleason 6 or less and T1c/T2a), only 26.1% were found to have pathologically-confirmed unilateral disease among the potential candidates for hemi-ablation. Even if the goal of hemi-ablation was only to remove of significant cancer or unfavorable pathology, such a goal would have only been achieved in about one third of our potential candidates for hemi-ablation. Moreover, even when limited to only those in the D’Amico low risk group, about half of the potential candidates for hemi-ablation were found to harbor unfavorable pathology or significant cancer in the unilateral lobe not suspected to harbor tumor preoperatively. Overall, the current study demonstrated that the combination of extended TRUS-guided prostate biopsy and mpMRI
did not provide reliable accuracy in the prediction of unilateral PCa, which is essential in the identification of appropriate candidates for hemi-ablative focal therapy.

Despite the appeal of performing organ-sparing treatment for PCa, concerns regarding the risk of failing to detect the significant tumor foci in untreated prostatic region largely limit the more widespread use of focal therapy. As widely known, PCa is often multifocal with incidence ranging from 67% to 87% [15]. On the other hand, it has been reported 20% of PCa patients have completely unilateral disease with small tumor volume [16]. Such cases can be considered appropriate for hemi-ablative focal therapy. Today, the widespread use of PSA screening has led to more men being diagnosed with PCa at earlier stage with smaller volume than ever [1]. As such, suitable candidates for focal therapy may increase as well. It would be important to develop tools for accurate detection of tumor foci in the prostate.

Several recent reports have offered promising findings on the accuracy of MRI in the depiction and localization of tumor foci in the prostate [17–20]. Others have reported that MRI may indeed be helpful in avoiding unnecessary biopsies [21]. A meta-analysis revealed that mpMRI has a sensitivity of 66–81% and specificity of 82–92% for PCa detection [7]. Such moderate sensitivity and high specificity of contemporary mpMRI for significant or index lesions and the ability to anatomically localize these lesions indicate that mpMRI may indeed be helpful tool in the selection of candidates for focal therapy. Nonetheless, studies evaluating the accuracy of mpMRI for the identification of unilateral PCa are lacking in the literature. Matsouka et al reported that diffusion-weighted MRI and a combined TRUS/transperineal biopsy technique with 14 cores showed a negative predictive value of 95.7% for predicting lobes with significant tumor foci [22]. It should be noted that insignificant PCa included Gleason score 3 + 4 PCa in their study. Tran et al evaluated the accuracy of mpMRI and transperineal template-guided mapping biopsy for identifying the locations of significant PCa in 50 subjects, they found that sensitivity, specificity, and negative predictive value for such combination for localizing the significant disease were 97%, 61%, and 91%, respectively [23]. A more recent

Fig 1. Patient selection flow diagram. MRI; Magnetic Resonance Imaging, DRE; Digital Rectal Exam.

https://doi.org/10.1371/journal.pone.0202872.g001
multicenter prospective study—funded by UK government—also demonstrate the significant correlation between mpMRI and pathological outcome of transperineal template-guided biopsy, showing the ability to rule out significant cancer with high accuracy, with 93% sensitivity and 89% negative predictive value [24]. The findings from these studies suggested that

Table 1. Clinicopathological characteristics of patients with unilateral prostatic lobe not suspected to harbor PCa by the combination of TRUS biopsy and mpMRI.

| Characteristics                        | Value | %    |
|----------------------------------------|-------|------|
| Number of patients                    | 335   |      |
| Age (yr, range)                        | 65.1 (45–82) |      |
| PSA (ng/ml, range)                     | 7.8 (2.2–21) |      |
| Prostate volume (cc)                   | 38.4 (12–64) |      |
| Clinical stage                         |       |      |
| T1b                                    | 1     | 0.3% |
| T1c                                    | 269   | 80.3%|
| ≥T2                                    | 66    | 19.7%|
| Biopsy Gleason score                   |       |      |
| ≤6                                     | 193   | 57.6%|
| 3 + 4                                  | 79    | 23.6%|
| 4 + 3                                  | 40    | 11.9%|
| ≥8                                     | 23    | 6.9% |
| Number of positive core                |       |      |
| ≤2                                     | 143   | 42.7%|
| 3–4                                    | 155   | 46.3%|
| ≥4                                     | 37    | 11.0%|
| D'Amico risk group                     |       |      |
| Low                                    | 115   | 34.3%|
| Intermediate                           | 185   | 55.2%|
| High                                   | 35    | 10.4%|
| Pathological Stage                     |       |      |
| T2a                                    | 26    | 7.8% |
| T2b                                    | 20    | 6.0% |
| T2c                                    | 259   | 77.3%|
| T3a                                    | 21    | 6.3% |
| T3b                                    | 9     | 2.7% |
| Lymph node status                      |       |      |
| Nx                                     | 56    | 16.7%|
| N0                                     | 274   | 81.8%|
| N1                                     | 5     | 1.5% |
| Pathological Gleason Score             |       |      |
| 3 + 3                                  | 52    | 15.5%|
| 3 + 4                                  | 185   | 55.2%|
| 4 + 3                                  | 88    | 26.3%|
| 4 + 4                                  | 9     | 2.7% |
| Gleason Score up/downgrade             |       |      |
| Upgrade                                | 172   | 51.3%|
| Downgrade                              | 7     | 2.1% |

Pca; prostate cancer, TRUS; transrectal ultrasonography, mpMRI; multiparametric magnetic resonance imaging

https://doi.org/10.1371/journal.pone.0202872.t001
mpMRI could be useful in the selection of candidates for hemi-ablative focal therapy by providing a high negative predictive value in the detection of significant PCa.

On the other hand, not all published reports have offered such promising data on the accuracy of mpMRI. Though not on mpMRI, Jeong et al. investigated the accuracy of prostate biopsy and conventional MRI in predicting the laterality of PCa [25]. In their series of men who underwent preoperative MRI and subsequent RP, the positive predictive value for predicting pathologic unilaterality was 34.8%, using an approach that combined extended TRUS-guided biopsy and conventional MRI. Analyzing patient who underwent preoperative mpMRI before RP, Rosenkrantz et al. reported that 36% of cancers that were underdetected with mpMRI had a Gleason score of $7$ [26]. Moreover, a study on pathologic analyses of RP specimen in patients who had negative finding from preoperative mpMRI found that 61.4% of subjects had a pathologic Gleason score $\geq 7$ [27]. These data on the rate of pathologically-confirmed significant cancers undetected by preoperative mpMRI would be supportive of the results from our study. Although recent reports have shown a relatively high accuracy of mpMRI in the localization of intra-prostatic tumor foci, there remains controversy, as can be seen from our findings as well as from other previous studies.

Table 2. Pathological outcome of unilateral lobe not suspected to harbor PCa by the combination of TRUS biopsy and mpMRI.

| Characteristics                        | Value | %   |
|----------------------------------------|-------|-----|
| Number of non-suspicious lobes         | 335   |     |
| No malignancy                          | 46    | 13.7%|
| Pathological Stage                     |       |     |
| T2                                     | 279   | 83.3%|
| T3a                                    | 6     | 1.8% |
| T3b                                    | 4     | 1.2% |
| Pathological Gleason score             |       |     |
| 3 + 3                                  | 75    | 22.4%|
| 3 + 4                                  | 130   | 38.8%|
| 4 + 3                                  | 80    | 23.9%|
| 4 + 4                                  | 4     | 1.2% |
| Tumor location                         |       |     |
| Transitional Zone                      | 131   | 39.1%|
| Peripheral Zone                        | 212   | 63.3%|
| Tumor volume (mL)                      |       |     |
| Global tumor volume                    |       |     |
| Median (range)                         | 0.86 (0.03–9.8) | |
| $<0.5$, n (%)                          | 93    | 27.8%|
| $\geq0.5$, n (%)                       | 196   | 58.5%|
| Main tumor volume                      |       |     |
| Median (range)                         | 0.61 (0.03–20.7) | |
| $<0.5$, n (%)                          | 132   | 39.4%|
| $\geq0.5$, n (%)                       | 157   | 46.9%|
| Number of tumors                       |       |     |
| 1                                      | 97    | 29.0%|
| $\geq2$                                | 192   | 57.3%|

Pca; prostate cancer, TRUS; transrectal ultrasonography, mpMRI; multiparametric magnetic resonance imaging

https://doi.org/10.1371/journal.pone.0202872.t002
Several factors may have contributed to such a discrepancy. First, most of the published studies on mpMRI in men who underwent RP included only a small number of highly selected subjects [22, 23]. In such studies, mpMRI was mostly performed prior to biopsy, which was not the case in this present study. Currently, MRI is still more frequently performed for staging purposes following tissue confirmation of PCa from biopsy rather than in pre-biopsy setting.

Table 3. Comparison of pathological outcomes of unilateral lobe not suspected to harbor PCa by the combination of TRUS biopsy and mpMRI between D’Amico low risk group and D’Amico intermediate to high risk group.

| Characteristics | D’Amico Low (n = 115) | D’Amico Intermediate to High (n = 220) | p-value |
|-----------------|-----------------------|----------------------------------------|---------|
| Value %         | Value %               |                                        |         |
| No malignancy   | 30 26.1%              | 16 7.3%                                | <0.01   |
| Pathological Stage T2 | 83 72.2%              | 196 89.1%                             |         |
| T3a             | 1 0.9%                | 5 2.3%                                |         |
| T3b             | 1 0.9%                | 3 1.4%                                | <0.01   |
| Pathological Gleason score 3 + 3 | 35 30.4%              | 40 18.2%                             |         |
| 3 + 4           | 33 28.7%              | 97 44.1%                              |         |
| 4 + 3           | 16 13.9%              | 64 29.1%                              |         |
| 4 + 4           | 1 0.9%                | 3 1.4%                                | <0.01   |
| Tumor volume (mL) | Global tumor volume |                                        |         |
| Median (range)  | 0.86 (0.03–9.8)       | 0.86 (0.03–9.8)                       |         |
| <0.5, n (%)     | 48 41.7%              | 45 20.5%                              |         |
| >=0.5, n (%)    | 37 32.2%              | 159 72.3%                             | <0.01   |
| Main tumor volume | Median (range)       |                                        |         |
| Median (range)  | 0.61 (0.03–20.7)      | 0.61 (0.03–20.7)                      |         |
| <0.5, n (%)     | 52 45.2%              | 80 36.4%                              | <0.01   |
| >=0.5, n (%)    | 33 28.7%              | 124 56.4%                             |         |
| Number of tumors 1 | 43 37.4%              | 54 24.5%                              |         |
| >=2             | 42 36.5%              | 150 68.2%                             | <0.01   |

Pca: prostate cancer, TRUS; transrectal ultrasonography, mpMRI; multiparametric magnetic resonance imaging

https://doi.org/10.1371/journal.pone.0202872.t003

Table 4. Absence rates of significant cancer, unfavorable disease, and dominant Gleason pattern ≥ 4 according to the subgroups.

| Pathology Result of Non-suspicious Lobe From RP Specimen | Whole Group (n = 335) | D’Amico Low (n = 115) | D’Amico Intermediate to High (n = 220) | Low vs Intermediate to High (p-value) |
|---------------------------------------------------------|-----------------------|-----------------------|----------------------------------------|-------------------------------------|
| Absence of Malignancy                                   | 46 (13.7%)            | 30 (26.1%)            | 16 (7.3%)                              | <0.01                              |
| Absence of Significant Cancer                           | 103 (30.7%)           | 55 (47.8%)            | 48 (21.8%)                             | <0.01                              |
| Absence of Unfavorable Pathology                        | 121 (36.1%)           | 65 (56.5%)            | 56 (25.5%)                             | <0.01                              |
| Absence of Dominant Gleason pattern 4 or 5             | 251 (74.9%)           | 98 (85.2%)            | 153 (69.5%)                            | <0.01                              |

RP: radical prostatectomy

https://doi.org/10.1371/journal.pone.0202872.t004
Pre-biopsy mpMRI may be associated with the possibility of selection bias, as it can influence the decision on whether to perform prostate biopsy or not. Although our study was retrospective in nature, it depicts a real-life situation on a relatively larger cohort of consecutive patients managed at our institution. Second, the difference in biopsy approach should be considered. Our patients underwent contemporary TRUS-guided biopsy, whereas other studies included patients who received transperineal mapping or template-guided biopsy. It has been reported that less than 40% of patients with unilateral disease on TRUS-guided biopsy actually had pathologically-confirmed unilateral disease on RP specimens [28]. Tumor foci not detected by TRUS-guided biopsy tend to be located more commonly in the anterior prostate than in the posterior prostate [29]. Recent studies showed that newer biopsy approaches, such as transperineal template-guided biopsy, enabled more efficient detection of tumor foci, resulting in superior accuracy [30, 31]. Since template-guided mapping biopsy offers systematic sampling of the entire prostate, it is considered to be the diagnostic tool for focal therapy. However, it cannot be denied that TRUS-guided biopsy, compared with newer biopsy techniques, is still more commonly performed in the actual clinical setting. Additionally, regardless of the version or type of MRI scanners used, the inter-observer variability should always be considered in studies on imaging findings [32]. Meanwhile, for our subjects, mpMRI was mostly performed with state-of-the-art 3-T scanners and analyzed by expert radiologists with more than 20 years of clinical experience. Overall, it can be stated that our study may be more reflective of true real-life contemporary clinical practice than many other relevant studies.

Our findings from real-life clinical practice revealed that the combination of contemporary extended TRUS-guided biopsy and mpMRI did not predict unilaterality of PCa with reliable accuracy. Therefore, the benefit of performing a repeat mpMRI-guided biopsy after the initial TRUS-guided biopsy, for the purpose of improving the accuracy of laterality prediction, such as in-bore biopsy, cognitive fusion or MRI/US fusion biopsy, might be limited. The mpMRI-guided biopsy before the initial biopsy could improve accuracy; however, to the best of our best knowledge, there is no published study on the specific subject. At this time point, a more accurate biopsy scheme is needed for the proper selection of candidates for hemi-ablative focal therapy. Although transperineal template-guided mapping biopsy and saturation biopsy approach may be more costly and likely to increase the level of patients’ burden and discomfort, such a scheme provides more precise representation of the intra-prostatic lesion. These new biopsy strategies should be thoroughly evaluated and refined to improve efficiency and safety for a wide application.

In the light of recent studies, mpMRI appears to be a promising modality for localization of tumor foci. However, real-time monitoring of focal therapy seems to be technically challenging. For real-time monitoring of focal therapy, newer multiparametric ultrasonography, such as

|                        | Sensitivity %, (95% CI) | Specificity %, (95% CI) | Positive Predictive Value %, (95% CI) | Negative Predictive Value %, (95% CI) | Positive Likelihood Ratio (95% CI) | Negative Likelihood Ratio (95% CI) |
|------------------------|-------------------------|--------------------------|---------------------------------------|---------------------------------------|----------------------------------|----------------------------------|
| Malignancy             | 52.9% (48.9% to 56.9%)  | 82.1% (69.6% to 91.1%)   | 95.8% (94.9% to 98.3%)                | 13.7% (12.1% to 15.6%)               | 2.96 (1.68 to 5.22)                | 0.57 (0.49 to 0.66)               |
| Significant Cancer     | 55.5% (51.1% to 59.8%)  | 69.1% (61.1% to 76.4%)   | 86.3% (83.0% to 89.0%)                | 30.8% (27.8% to 33.9%)               | 1.80 (1.40 to 2.31)                | 0.64 (0.56 to 0.74)               |
| Unfavorable Pathology  | 56.4% (51.9% to 60.9%)  | 67.6% (60.2% to 74.4%)   | 82.7% (79.2% to 85.7%)                | 36.1% (32.9% to 39.5%)               | 1.74 (1.39 to 2.18)                | 0.64 (0.56 to 0.74)               |

TRUS; transrectal ultrasonography, mpMRI; multiparametric magnetic resonance imaging

https://doi.org/10.1371/journal.pone.0202872.t005
as shear wave elastography and contrast-enhanced ultrasound, may well be more appropriate in the future. [6]

The present study has some limitations to consider. The retrospective design may be a limiting factor to our data. Moreover, only patients who underwent definitive treatment of radical prostatectomy were included in the study, which may have introduced selection bias. However, for a series on preoperative mpMRI in a RP cohort, the number of subjects in our study is relatively larger than or comparable to other similar series. Meanwhile, clinicopathologic profiles of our subjects appeared to be relatively more aggressive (higher PSA level, higher rate of high-grade disease) than those reported from western series. The rate of PSA screening in Asia is still not as high as in Western countries [33]. Although there is an on-going trend of decreasing gap, PCas in Asian men are diagnosed at relatively higher PSA, higher Gleason score, and higher stage than in their Western counterparts.

Conclusions
In this study, we observed that the combination of multi-core TRUS-guided prostate biopsy and mpMRI did not provide reliable accuracy in predicting the true unilaterality of PCa in patients who underwent prostate biopsy, preoperative mpMRI, and RP. This suggests that improvement on biopsy and MRI technique is warranted for an accurate localization of tumor foci, which is crucial for the appropriate selection of candidates for focal therapy.

Author Contributions
Conceptualization: Hakjong Lee, Sung Kyu Hong.
Data curation: Jung Jun Kim, Taejin Kim, Hakjong Lee, Seok-Sooy Byun, Gheeyoung Choe, Sung Kyu Hong.
Formal analysis: Jung Jun Kim, Hakjong Lee, Sung Kyu Hong.
Investigation: Jung Jun Kim, Taejin Kim, Gheeyoung Choe, Sung Kyu Hong.
Methodology: Hakjong Lee, Gheeyoung Choe, Sung Kyu Hong.
Project administration: Sung Kyu Hong.
Resources: Seok-Sooy Byun, Sang Eun Lee, Sung Kyu Hong.
Supervision: Hakjong Lee, Seok-Sooy Byun, Sang Eun Lee, Sung Kyu Hong.
Validation: Hakjong Lee, Sung Kyu Hong.
Writing – original draft: Jung Jun Kim, Sung Kyu Hong.
Writing – review & editing: Jung Jun Kim, Sung Kyu Hong.

References
1. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. The Journal of urology. 2007; 178:S14–S9. https://doi.org/10.1016/j.juro.2007.03.135 PMID: 17644125
2. Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. European urology. 2014; 66:732–51. https://doi.org/10.1016/j.eururo.2013.05.048 PMID: 23769825
3. Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. The lancet oncology. 2012; 13:622–32. https://doi.org/10.1016/S1470-2045(12)70121-3 PMID: 22512844
4. Bahn D, Castro AA, Gill IS, Hung AJ, Silverman P, Gross ME, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3 years. European urology. 2012; 62:55–63. https://doi.org/10.1016/j.euro.2012.03.006 PMID: 22445223

5. Cordeiro ER, Cathelineux X, Thüroff S, Marberger M, Crouzet S, de la Rosette JJ. High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. BJU International. 2012; 110:1228–42. https://doi.org/10.1111/j.1464-1015.2012.11262.x PMID: 22872199

6. Fejoo ERC, Sivaraman A, Barret E, Sanchez-Salas R, Galiano M, Rozet F, et al. Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes. European urology. 2016; 69:214–20. https://doi.org/10.1016/j.euro.2015.06.018 PMID: 26164416

7. de Rooij M, Hamoen EH, Fütterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. American Journal of Roentgenology. 2014; 202:343–51. https://doi.org/10.2214/AJR.13.11046 PMID: 24450675

8. Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L, et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. The Journal of urology. 2014; 192:67–74. https://doi.org/10.1016/j.juro.2014.01.014 PMID: 24518762

9. Filson CP, Natarajan S, Margolis DJ, Huang J, Lieu P, Dorey FJ, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer. 2016; 122:884–92. https://doi.org/10.1002/cncr.29874 PMID: 26749141

10. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging–reporting and data system: 2015, version 2. European urology. 2016; 69:16–40. https://doi.org/10.1016/j.euro.2015.08.052 PMID: 26427566

11. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of surgical oncology. 2010; 17:1471–4. https://doi.org/10.1245/s10434-010-0985-4 PMID: 20180029

12. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Committee IG. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostate carcinoma. The American journal of surgical pathology. 2005; 29:1228–42. PMID: 16096414

13. Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf J-B, et al. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. European urology. 2008; 54:1306–13. https://doi.org/10.1016/j.eururo.2007.11.057 PMID: 18083294

14. Starney TA, Freilha F, McNeel J, Redwine E, Whittmore A, Schmid H. Localized prostate cancer. Cancer. 1993; 71:933–38. PMID: 7679045

15. Meiers I, Waters DJ, Bostwick DG. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007; 110:906–10. https://doi.org/10.1002/cncr.22858 PMID: 17587207

16. Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007; 110:906–10. https://doi.org/10.1002/cncr.22858 PMID: 17587207

17. Baco E, Ukimura O, Rud E, Vlatkovic L, Svindland A, Aron M, et al. Magnetic resonance imaging–transrectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. European urology. 2015; 67:787–94. https://doi.org/10.1016/j.eururo.2014.08.077 PMID: 25240973

18. Radtke JP, Schwab C, Wolf MB, Freitag MT, Alt CD, Kesch C, et al. Multiparametric magnetic resonance imaging (MRI) and MRI–transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. European urology. 2016; 70:846–53. https://doi.org/10.1016/j.euro.2015.12.052 PMID: 26810346

19. Berkowitz BA, Lewin AS, Biswal MR, Bredell BX, Davis C, Roberts R. MRI of Retinal Free Radical Production With Laminar Resolution In VivoFree Radical Production With Laminar Resolution In Vivo. Investigative ophthalmology visual science. 2016; 57:577–85.

20. Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. European urology. 2015; 67:569–76. https://doi.org/10.1016/j.eururo.2014.08.078 PMID: 25257029

21. Ahmed HU, Bosaily AE-S, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet. 2017; 389:815–22.

22. Matsuoka Y, Numao N, Saito K, Tanaka H, Kumagai J, Yoshida S, et al. Candidate selection for quadrant-based focal ablation through a combination of diffusion-weighted magnetic resonance imaging and prostate biopsy. BJU International. 2016; 117:94–101. https://doi.org/10.1111/bju.12901 PMID: 25124332
23. Tran M, Thompson J, Böhm M, Pullbrook M, Moses D, Shnier R, et al. Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemiablative focal therapy. BJU international. 2016; 117:48–54. https://doi.org/10.1111/bju.13090 PMID: 25682968

24. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet (London, England). 2017; 389:815–22.

25. Jeong CW, Ku JH, Moon KC, Hong SK, Byun S-S, Cho JY, et al. Can conventional magnetic resonance imaging, prostate needle biopsy, or their combination predict the laterality of clinically localized prostate cancer? Urology. 2012; 79:1322–8. https://doi.org/10.1016/j.urology.2012.01.080 PMID: 22656409

26. Rosenkrantz AB, Mendronis S, Babb JS, Taneja SS. Prostate cancer foci detected on multiparametric magnetic resonance imaging are histologically distinct from those not detected. The Journal of urology. 2012; 187:2032–8. https://doi.org/10.1016/j.juro.2012.01.074 PMID: 22498205

27. Branger N, Maubon T, Traumann M, Thomassin-Piana J, Brandone N, Taix S, et al. Is negative multi-parametric magnetic resonance imaging really able to exclude significant prostate cancer? The real-life experience. Bju international. 2017; 119:449–55. https://doi.org/10.1111/bju.13657 PMID: 27618134

28. Polascik TJ, Mayes JM, Schroeck FR, Sun L, Madden JF, Moul JW, et al. Patient selection for hemiablative focal therapy of prostate cancer. Cancer. 2009; 115:2104–10. https://doi.org/10.1002/cncr.24258 PMID: 19288576

29. Numao N, Kawakami S, Sakura M, Yoshida S, Koga F, Saito K, et al. Characteristics and clinical significance of prostate cancers missed by initial transrectal 12-core biopsy. BJU international. 2012; 109:665–71. https://doi.org/10.1111/j.1464-410X.2011.10427.x PMID: 21939488

30. van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, et al. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. European urology. 2014; 65:1078–83. https://doi.org/10.1016/j.eururo.2014.01.001 PMID: 24444476

31. Kawakami S, Hyochi N, Yonese J, Yano M, Fuji Y, Kageyama Y, et al. Three-dimensional combination of transrectal and transperineal biopsies for efficient detection of stage T1c prostate cancer. International journal of clinical oncology. 2006; 11:127–32. https://doi.org/10.1007/s10147-005-0547-0 PMID: 16622747

32. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. European radiology. 2012; 22:746–57. https://doi.org/10.1007/s00330-011-2377-y PMID: 22323008

33. Zhang K, Bangma CH, Roobol MJ. Prostate cancer screening in Europe and Asia. Asian Journal of Urology. 2016.